Getein Biotech, Inc.

Getein Biotech, Inc. saw a notable stock decline amid broader market losses, with its price reaching an intraday low. Despite a slight weekly recovery, the company has faced ongoing challenges, including negative results over ten quarters and declining net sales, while maintaining a dividend yield of 2.07%.

Getein Biotech, Inc. experienced a notable increase in stock performance, rising significantly today while the broader market declined. Over the past week, the company has shown strong momentum, with substantial gains in both weekly and monthly performance. Despite challenges in growth, today's activity marks a rebound for the stock.

Getein Biotech, Inc. has seen a notable increase in its stock performance, contrasting with the broader market. Over the past week, the stock rose significantly, while year-to-date gains also reflect strong performance. However, the company faces long-term growth challenges, including declining net sales and consecutive negative quarterly results.

Getein Biotech, Inc. has seen a notable increase in its stock performance, gaining 10.02% on March 17, 2026, and reaching an intraday high of CNY 9.44. Despite long-term challenges, the company maintains a market capitalization of CNY 4,407 million and a dividend yield of 2.07%.